ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Inclusion Criteria:

• Male or female, aged 18 years and above

• Tumor tissue obtained on a screening consent is available.

• Confirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted OligodendrogliomaWHO grade 2 or WHO grade 3, more than 12 weeks from completion of radiation.

• Karnofsky Performance Status ≥ 60

• Must be a candidate for surgery/biopsy

• Adequate bone marrow and organ function as defined below:

• ANC ≥ 1,000/mcL

• Platelets ≥ 100,000/mcL

• Hemoglobin ≥ 9 g/dL (can be transfused)

• Serum creatinine ≤ 1.5 x IULN OR Creatinine clearance by Cockcroft-Gault ≥ 60mL/min for patients with serum creatinine > 1.5 x IULN

• Serum total bilirubin ≤ 1.5 x IULN OR Direct bilirubin ≤ IULN for patients withtotal bilirubin > 1.5 x IULN

• AST (SGOT) and ALT (SGPT) ≤ 3 x IULN

• For females of childbearing potential, negative serum pregnancy test at enrollment

• For women and men of childbearing potential (WOCBP) must be willing to useacceptable contraceptive methods

Exclusion Criteria:

• Disease progression during treatment with an anti-IDH-1 or anti IDH-2

• Prior invasive malignancy (except for non-melanomatous skin cancer) unless diseasefree for ≥ 3 years.

• Metastases detected below the tentorium or beyond the cranial vault andleptomeningeal involvement.

• Multifocal disease.

• Corticosteroids equivalent to ≥ 4mg dexamethasone daily.

• HIV, Hepatitis B, or Hepatitis C seropositive.

• Known active infection or immunosuppressive disease.

• Autoimmune disease requiring medical management with immunosuppressant.

• Pregnancy or lactation, due to possible adverse effects on the developing fetus orinfant.

• Treatment with another investigational drug or other intervention within 30 daysprior to projected first dose of study treatment (Priming phase with TTRNA-DC).

• Severe, active co-morbidity, defined as follows:

• Unstable angina and/or congestive heart failure requiring hospitalization.

• Transmural myocardial infarction within the last 6 months.

• Acute bacterial or fungal infection requiring intravenous antibiotics at timeof enrollment.

• Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illnessrequiring hospitalization or precluding study therapy.

• Hepatic insufficiency resulting in clinical jaundice and/or coagulationdefects.

• Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition.The need to exclude patients with AIDS from this protocol is necessary becausethe treatments involved in this protocol may be significantlyimmunosuppressive.

• Major medical illnesses or psychiatric impairments that, in the investigator'sopinion, will prevent administration or completion of protocol therapy.